Compare · GCTK vs WST
GCTK vs WST
Side-by-side comparison of GlucoTrack Inc. (GCTK) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GCTK and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.96B, about 13682.0x GCTK ($2.0M).
- GCTK has been more active in the news (8 items in the past 4 weeks vs 3 for WST).
- WST has more recent analyst coverage (20 ratings vs 0 for GCTK).
- Company
- GlucoTrack Inc.
- West Pharmaceutical Services Inc.
- Price
- $0.74-7.72%
- $383.81+0.18%
- Market cap
- $2.0M
- $26.96B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 0
- 20
GlucoTrack Inc.
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest GCTK
- SEC Form PRE 14A filed by GlucoTrack Inc.
- Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications
- Amendment: SEC Form S-1/A filed by GlucoTrack Inc.
- SEC Form 425 filed by GlucoTrack Inc.
- Amendment: SEC Form 8-K/A filed by GlucoTrack Inc.
- Lōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität Paderborn
- Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14
- GlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™
- SEC Form 424B5 filed by GlucoTrack Inc.
Latest WST
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences